$BPTH Biopath Holdings $2.52
MarCap $213M
O/S 89M
Institutional holding 29%
Cash $16M
Debt $300K
Cash Burn Rate $1.8M last quarter
52 wk high $5.25
52 wk low $1.80
Advancing siRNA technology anticancer agents.
Liposomal Grb-2, just completed Phase I for blood cancers treatment. Liposomal Grb-2, is in a Phase I study for blood cancers and in preclinical studies for triple negative and inflammatory breast cancers. Bio-Path’s second drug candidate, also a liposomal antisense drug, is ready for the clinic where it will be evaluated in lymphoma and solid tumors.
This is a MD Anderson spin-off start-up. Uplisted to NASDAQ this last year and added to the Russell this last quarter.
They will ring the closing bell at the NASDAQ today. We may see a PR EOD about data or being invited to present at ASH. Otherwise, I am waiting to hear if they are late breaking abstract.
Technically, this one has double bottomed at $2 recently after sell off this summer. Currently, it has justr closed above its 50d MA in a bullish move off support. MACD poaitive divergence, RSI and MFI rising. Today it is forming a dragonfly if not long handled hammer right at resistance. Any additional volume flow or good news could send this back to its 200d MA at just under $3. APossible solid 20% move here.
AI
